Paul Howard is a Partner and founder of Mediphase
Venture Partners. Mr. Howard concentrates his efforts on
the Life Sciences companies in the portfolios. He has invested
in over 25 private companies that include Tularik, Exelixis,
CV Therapeutics, Cubist, Rosetta Inpharmatics, Dyax and LJL
Biosytems. Mr. Howard serves on the Board of Directors of Supplemental Health Care and Serenex.
Prior to founding Mediphase Venture Partners, Mr. Howard
was a Senior Vice President at Hambrecht & Quist Capital
Management in Boston from 1992-1999, where he was responsible
for managing the fund's biotechnology investments. From 1983-1990
Mr. Howard was a Senior Technical Sales Executive for the
Miles Biotechnology Division of Bayer A.G.
Mr. Howard earned an A.B. from Bowdoin College in 1981,
an M.S. from the University of Massachusetts, Amherst in
1983, and an S.M. from the Sloan School of Management at
M.I.T. in 1992.